EPHB4 and neoplasm: Molecular approaches have identified some candidate biomarkers related to pericytes; high levels of tumour expression of a gene involved in pericyte-driven tumour maturation, EPHB4, was found to be associated with decreased OS of CRC patients treated with bevacizumab and pericyte germline polymorphisms in mCRC patients treated with bevacizumab plus chemotherapy are associated with clinical outcome [33, 34].